Lanreotid Amdipharm

Lanreotide acetate, the active ingredient in Lanreotid Amdipharm, is a somatostatin analog presented as a subcutaneous formulation for injection use. It mimics natural somatostatin to suppress excess hormone secretion and is employed to manage hormone‑related disorders such as acromegaly and certain neuroendocrine tumors in adult patients.

GNH USA supplies Lanreotid Amdipharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, specialty clinics and pharmacies worldwide, backed by established cold‑chain logistics and regulatory expertise and ensures timely delivery to global markets.

Lanreotide acetate is used in endocrine disorders that involve excess hormone secretion. - Acromegaly: reduces excess growth hormone and IGF‑1 levels, helping control disease activity. - Gastroenteropancreatic neuroendocrine tumors (GEP‑NETs): inhibits tumor growth and hormone secretion. - Carcinoid syndrome associated with NETs: alleviates flushing and diarrhea by suppressing serotonin release.

Common Side Effects: - Injection site pain or erythema - Diarrhea or loose stools - Nausea or abdominal discomfort - Headache - Constipation - Fatigue Serious or Rare Side Effects: - Gallbladder disease or biliary sludge - Hyperglycemia or new‑onset diabetes - Acute pancreatitis - Severe allergic reactions (anaphylaxis) - Injection site necrosis or infection - Cardiovascular events such as arrhythmia

Lanreotide acetate requires careful monitoring and patient counseling. - Glucose monitoring: assess blood sugar levels regularly, especially in diabetic patients. - Gallbladder assessment: evaluate for gallstones or biliary symptoms before and during therapy. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Hepatic or renal impairment: adjust therapy based on clinical judgment. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lanreotide acetate may interact with several drug classes. Major Interactions (Avoid): - Concomitant use with other somatostatin analogues: increased risk of gallbladder complications. - Cyclosporine: may enhance cyclosporine levels, requiring dose adjustment. Moderate Interactions (Monitor Closely): - Oral glucose‑lowering agents: may require dose modification due to altered glucose metabolism. - Antidiabetic insulin: monitor for hypoglycemia. - Medications affecting gastrointestinal motility: potential additive effects on absorption.